Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 25, 2021

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions
Advanced Breast Cancer
Interventions
DRUG

Talazoparib Oral Capsule

\- Patients will receive Talazoparib 1 mg orally once daily continuously, with or without food. Laboratory values will be monitored every 4 weeks until progression or unacceptable toxicity. Dose modifications should be made based on the observed toxicity

Trial Locations (1)

Unknown

RECRUITING

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER